Tamsulosin Hydrochloride Capsule
Product Images NDC 70518-2052

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 70518-2052). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Label for Tamsulosin Hydrochloride 0.4 mg oral capsules, quantity 90, repackaged by RemedyRepack Inc. The label includes the NDC number 70518-2052-00, manufacturer Aurobindo from Nagar, India, and storage instructions with temperature ranges. A QR code is also present on the label.*

FDA Label Image

Tamsulosin HCl 0.4mg 70518 2052 01

Label for Tamsulosin Hydrochloride 0.4 mg capsules, quantity 30, repackaged by RemedyRepack Inc. The label notes the NDC 70518-2052-01 and states it is for prescription use only. The label includes storage instructions and manufacturer information for Aurobindo, India.*

FDA Label Image

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-dose Administration Of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted And Fed Conditions (n=8) (Tamsulosin Fig1)

A line graph showing mean plasma concentrations of Tamsulosin Hydrochloride over 36 hours after a single 0.4 mg capsule dose under fasted and fed conditions in eight subjects. The Y-axis depicts plasma concentration (ng/mL), and the X-axis represents time in hours. Two lines compare concentration profiles for fasted (dashed) and fed (solid) states.*

FDA Label Image

Figure 2a Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 1 (Tamsulosin Fig2)

Line graph titled 'Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 1' showing mean change over treatment duration in weeks. The graph compares three groups: 0.8 mg, 0.4 mg Tamsulosin Hydrochloride, and placebo, with symptom scores on the vertical axis and treatment duration on the horizontal axis. Both Tamsulosin doses show greater decreases in symptom scores compared to placebo over 13 weeks.*

FDA Label Image

Figure 2b Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 2 (Tamsulosin Fig3)

A line graph titled 'Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 2' showing mean symptom score changes over a 13-week treatment duration. The x-axis represents weeks of treatment, and the y-axis shows mean change in symptom score. Three treatment groups are compared: 0.8 mg and 0.4 mg doses of Tamsulosin Hydrochloride, and placebo. Both Tamsulosin doses show greater symptom improvement over time compared to placebo, with data points noted at several time intervals up to 13 weeks (LOCF).*

FDA Label Image

Figure 3a Mean Increase In Peak Urine Flow Rate (ml/sec) Study 1 (Tamsulosin Fig4)

A line graph titled 'Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 1' showing the mean change in urine flow rate over weeks of treatment. It compares three treatments: 0.8 mg dose, 0.4 mg dose, and placebo, with data points from baseline to 13 weeks and last observed carried forward (LOCF). The 0.8 mg and 0.4 mg treatment lines show greater increases than placebo throughout the duration.*

FDA Label Image

Figure 3b Mean Increase In Peak Urine Flow Rate (ml/sec) Study 2 (Tamsulosin Fig5)

A line graph showing the mean increase in peak urine flow rate (mL/sec) over the duration of treatment (weeks) for three groups: 0.8 mg, 0.4 mg, and placebo. The x-axis represents treatment duration from 0 to 13 weeks and LOCF, while the y-axis represents mean change in mL/sec up to 3.0. The graph compares treatment effects with distinct markers for each group.*

FDA Label Image

Chemical Structure (Tamsulosin Str)

Chemical structure of Tamsulosin Hydrochloride, illustrated as a molecular diagram showing its atomic composition and bonding layout.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.